Journal: Open Access Rheumatology : Research and Reviews

Article Title: Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes

doi: 10.2147/OARRR.S363736

Figure Lengend Snippet: Antibodies Employed for Western Blotting or Immunohistochemistry

Article Snippet: STAT1 , Cell Signaling Technology , 9176 , 1:1000.

Techniques: Western Blot

Journal: Open Access Rheumatology : Research and Reviews

Article Title: Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes

doi: 10.2147/OARRR.S363736

Figure Lengend Snippet: Cytokine rhIL-6 induced phosphorylation of STAT1 and STAT3 in C28/I2 chondrocytes and NHC. ( A ) Immunoblot analysis of p-STAT3, total STAT3, and GAPDH in whole cell lysate from C28/I2 cells. ( B ) Immunoblot analysis of p-STAT1, total STAT1, and GAPDH in whole cell lysate from C28/I2 cells. ( C ) Relative abundance of p-STAT3, total STAT3, p-STAT1, and total STAT1 normalized to GAPDH in C28/I2 cells treated as described. ( D ) Immunoblot analysis of p-STAT3, total STAT3, p-STAT1, total STAT1, and GAPDH in whole cell lysate from NHC. ( E ) Relative abundance of p-STAT3, total STAT3, p-STAT1, and total STAT1 normalized to GAPDH in NHC cells treated as described. Immunoblot data is representative of Mean ± Standard Deviation; N=4; *p<0.05, **p<0.01, ***p<0.003.

Article Snippet: STAT1 , Cell Signaling Technology , 9176 , 1:1000.

Techniques: Western Blot, Standard Deviation

Journal: Open Access Rheumatology : Research and Reviews

Article Title: Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes

doi: 10.2147/OARRR.S363736

Figure Lengend Snippet: Percent Change in STAT Proteins in Response to IL-6

Article Snippet: STAT1 , Cell Signaling Technology , 9176 , 1:1000.

Techniques:

Journal: Open Access Rheumatology : Research and Reviews

Article Title: Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes

doi: 10.2147/OARRR.S363736

Figure Lengend Snippet: Effect of Tofacitinib on rhIL-6 induced p-STAT3 and p-STAT1 in NHC and C28/I2. NHC and C28/I2 were pre-incubated with Tofacitinib (2.5nM, 20nM, 50nM, or 100 nM) for 30 min and then treated with rhIL-6 (20ng/mL) and Tofacitinib (2.5nM, 20nM, 50nM, or 100nM) concomitantly for 30 min. ( A ) Immunoblot analysis of p-STAT3, total STAT3, p-STAT1, total STAT1, and GAPDH in whole cell lysate from NHC or C28/I2 cells. ( B ) Relative abundance of p-STAT1 or p-STAT3 normalized to GAPDH in NHC or C28/I2 cells treated as described. Immunoblot data is representative of Mean ± Standard Deviation; N=4; *p<0.05, **p<0.01, ***p<0.002.

Article Snippet: STAT1 , Cell Signaling Technology , 9176 , 1:1000.

Techniques: Incubation, Western Blot, Standard Deviation

Journal: Nature Communications

Article Title: Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome

doi: 10.1038/ncomms9470

Figure Lengend Snippet: ( a ) Schematic representations of mutations in JAK1, JAK3, STAT3 and STAT5B identified in primary SS samples and the Hut-78 SS-derived cell line. ( b ) Dose–response curves for two primary SS leukaemic cells (SS29 and SS87), the negative control cell lines (HH and Jurkat) and the positive control cell line (Mac-1) after 48 h of treatment with JAK inhibitor I. All experiments were performed in triplicate and error bars represent s.d's (*** P <0.001, T -test). ( c ) Time–response curve for the two primary Sézary syndrome leukaemic cells (SS29 and SS87), the negative control cell lines (HH and Jurkat) and the positive control cell line (Mac-1) treated with 3 μM of JAK inhibitor I. All experiments were performed in triplicate and error bars represent s.d.'s (** P <0.01 and *** P <0.001 T -test). ( d ) Phosphorylation of STAT1, STAT3 and STAT5 in the two primary SS leukaemic cells (SS29 and SS87), the negative control cell lines (HH and Jurkat) and the positive control cell line (Mac-1) treated with 3 μM of JAK inhibitor I for 4 h.

Article Snippet: The following primary antibodies were obtained from Cell Signaling Technology: STAT1 (clone 9H2, 1/1,000), p-STAT1 (clone 58D6, 1/1,000), STAT3 (clone 79D7, 1/1,000), p-STAT3 (clone M9C6, 1/1,000), STAT5 (polyclonal, 1/1,000) and p-STAT5 (clone D47E7, 1/1,000).

Techniques: Derivative Assay, Negative Control, Positive Control, Phospho-proteomics